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Abstract
Interferon beta (IFNb) is the most common immunomodulatory treatment for relapsing-remitting multiple sclerosis (RRMS).
However, some patients fail to respond to treatment. In this study, we identified putative clinical response markers in the
serum and plasma of people with multiple sclerosis (MS) treated with IFNb. In a discovery-driven approach, we use 2D-
difference gel electrophoresis (DIGE) to identify putative clinical response markers and apply power calculations to identify
the sample size required to further validate those markers. In the process we have optimized a DIGE protocol for plasma to
obtain cost effective and high resolution gels for effective spot comparison. APOA1, A2M, and FIBB were identified as
putative clinical response markers. Power calculations showed that the current DIGE experiment requires a minimum of 10
samples from each group to be confident of 1.5 fold difference at the p,0.05 significance level. In a complementary
targeted approach, Cytometric Beadarray (CBA) analysis showed no significant difference in the serum concentration of IL-6,
IL-8, MIG, Eotaxin, IP-10, MCP-1, and MIP-1a, between clinical responders and non-responders, despite the association of
these proteins with IFNb treatment in MS.
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Introduction
Multiple sclerosis (MS) is a chronic, inflammatory, and
demyelinating autoimmune disorder of the central nervous system
(CNS). The disease course of relapsing remitting (RRMS) involves
periods of clinical remission interspersed by exacerbations or
relapses, which vary in their severity and duration. After many
years of RRMS, the patient may enter a secondary progressive
phase (SPMS) where the symptoms and nerve function gradually
worsen with or without relapses. IFNb treatment significantly
reduces the frequency of relapses, lesion load, and disability in
RRMS and SPMS patients [1,2]. However, up to a third of
patients do not respond to this therapy [3,4]. Amongst them, a
number of patients develop antibodies to IFNb that prevent
binding of the protein to its receptor (neutralizing antibodies:
NABs), reducing or abrogating the therapeutic effect of IFNb
[5,6]. It is important to identify people who do not respond
clinically to IFNb promptly, so they can be treated with less
immunogenic IFNb or alternate therapies at an early stage in the
disease course [7,8]. It has been shown that RRMS patients who
are clinical responders to IFNb treatment show a more
inflammatory and less neurodegenerative disease at the com-
mencement of the treatment compared to those who do not [9],
however no specific biomarkers were found to differentiate these
groups.
The aim of this study was to identify clinical response markers to
IFNb treatment in MS using proteomics. Discovery-driven and
targeted protein approaches were used. Discovery driven proteo-
mic approaches were first employed to generate the MS specific
protein profile from cerebrospinal fluid CSF [10–12]. A 2D-DIGE
approach was recently used to identify CSF markers in MS after
comparison with other neurological disorders [13,14]. 2D-DIGE
was also used in a study to differentiate the CSF proteome of
clinically isolated syndrome (CIS) patients that develop MS from
the ones that remained CIS [15]. 2D-gel electrophoresis (2DGE)
has been previously used to characterize the effect of serum from
MS patients with and without IFNb treatment on human cerebral
endothelial cells [16]. However, to our knowledge, none of these
techniques have previously been used in examining clinical
response to IFNb treatment in MS. We hypothesised that proteins
which differ in abundance between the plasma proteome of
clinical responders and non-responders to IFNb could serve as
clinical response markers for treatment with IFNb. Furthermore,
these proteins would be able to be identified using difference in-gel
electrophoresis (DIGE) and mass spectrometry.
In any complex proteomic experiment, it is critical to determine
the sample size required to provide sufficient statistical power to
detect biologically significant changes [17–19]. Hunt et al. [18]
established a protocol for optimizing experimental design. In this
paper, we adopt this approach, using a relatively small sample size
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,to enable accurate determination of statistical power while
simultaneously identifying an initial set of putative biomarkers.
Another important aspect of a DIGE study is optimizing sample
preparation to simplify the protocol and obtain a high resolution
gel. To obtain that, we have compared different depletion and
desalting techniques to remove the most abundant proteins and
achieve better protein separation respectively.
The targeted approach was employed to identify lower abundant
clinical response markers which may be undetectable by discovery
driven approaches such as 2D-DIGE, either because more highly
abundant proteins obscure their presence or because the removal of
highly abundant proteins alsodepletes lower abundant proteins, like
cytokines and chemokines, bound to these proteins [20]. In the
targeted approach, we hypothesised that protein markers previously
associated with IFNb treatment, such as chemokines and cytokines,
would also be markers of clinical response. In MS, chemokines act
as chemoattractants: recruiting immune cells and the proinflam-
matory cytokines they secrete, such as IL-2, IFNc, and TNFa,
which promote processes leading to demyelination [21]. In addition
they upregulate adhesion molecule expression which will assist in
transendothelialmigrationofautoreactiveimmune cellsthroughthe
blood brain barrier (BBB) [22]. IL-8 [23,24], IP-10 [25], MCP-1
[26,27], MIP-1a [28],andMIG[29] levels were previouslyfoundto
be differentially expressed in sera from patients with IFNb treated
MS as compared to untreated MS patients. Although changes in
serum Eotaxin are not known to be directly associated with IFNb
treatment,it is regulatedbyTh2cell mediated cytokines [30], which
play a significant role in the IFNb treatment mechanism [31] is also
found to be reduced in CSF from people with MS as compared to
HC [32]. Th2 induced IL-6 was the only anti-inflammatory
cytokine chosen for the current study, as its levels are increased in
the serum of MS patients following IFNb administration [33].
Despite their previous associations with IFNb treatment, the status
ofthesechemokinesandIL-6 asclinicalresponsemarkerstoIFNbis
unknown and will be explored in this study.
Materials and Methods
Ethics approval
This study was approved by the Sydney West Area Health
Service Human Research Ethics Committee (HREC2006/2/
4.33(2310)).
Sample collection
Discovery driven approach. Fresh blood was collected
from 3 individuals who showed a clinical response to treatment
(clinical responders - CRs) and 3 individuals who did not show a
clinical response (clinical non-responders - CNRs) in P100 tubes
(BD bioscience, NJ, US) 24 hours after IFNb injection. P100
tubes were used to enable greater recovery and preservation of
plasma proteins. Each group had two RRMS and one secondary
progressive MS patient (SPMS); the response status was defined
in different ways for each group. All six patients were under the
care of a neurologist with special interest in MS and had definite
MS by the McDonald criteria [34]. The RRMS CNRs (n=2)
had a history of at least one relapse in the last 2 years as
compared to none for CRs (n=2) since the commencement of
their treatment (Table 1). The SPMS patient CNR (n=1)
showed an annual increase in the disability index (Expanded
Disability Status Scale (EDSS) score) during the last year of IFNb
treatment while the SPMS CR (n=1) had no change in EDSS
(Table 1). In addition, MRI scans of the SPMS CNR revealed
greater degree in progression of cerebral atrophy as compared to
the SPMS CR during the last year of treatment. The tubes
were centrifuged at 2500 g for 10 minutes at 20uC, within
2 hours of blood collection. The separated plasma was
immediately aliquoted and stored at 280uC to prevent protein
degradation. Individual aliquots were prepared to prevent
freeze-thaw cycles.
Targeted approach. Serum samples were obtained from 18
clinical responders (CR) and 19 clinical non-responders (CNR) to
IFNb treatment from diagnostic laboratories across Australia, as a
part of a Neutralizing Antibody (NAB) testing service. 27 of those
patients were negative for NAB (NAB–ve) while 10 were NAB-
positive (NAB+ve). Patients gave informed consent for their
neurologists to provide relapse histories for this study. The
patients were classified as CR if they had no relapses during the
previous year of treatment [3]. Otherwise, they were classified as
CNR. Patient demographics are shown in Table 2. IFNb treated
patients with serum titres of 20 neutralizing units/ml or greater for
two consecutive measurements at a 3 month interval using the
cytopathic effect (CPE) bioassay (measures the serum
concentration required to neutralize the antiviral activity of the
IFNb) were considered NAB+ve [35]. Otherwise they were
considered NAB-ve. The samples were stored at 220uC until
used. Serum was diluted 1:4 for the chemokine analysis for optimal
results.
2D- gel electrophoresis protocol optimization
Prior to 2D-DIGE, the process for 2D-gel electrophoresis was
optimized. Several commonly used proteomic techniques were
trialled in various combinations to identify the optimal technique
Table 1. Demographics and clinical status of patients used in discovery-driven approach.















1 CR F 46 0.4 0 - - RRMS Avonex Cy3
2 CR F 28 1 0 - - RRMS Betaferon Cy5
3 CR F 46 - - 6 6 SPMS Rebiff Cy3
4 CNR M 30 0.5 .1 - - RRMS Avonex Cy5
5 CNR F 42 - - 6 7 SPMS Betaferon Cy3
6 CNR F 32 1 1 - - RRMS Avonex Cy5
Dyes were swapped for one CR and one CNR to remove dye bias.
*Relapses before and after are the annualised relapse rates before and after commencement of IFNb treatment respectively for RRMS patients. EDSS before and after
gives annual EDSS score before and after the last year of IFNb therapy respectively for SPMS patients.
doi:10.1371/journal.pone.0010484.t001
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below. All the optimization steps were carried out using 11 cm
IPG strips and 4–15% pre-cast SDS-PAGE gels (Bio-Rad
Laboratories, CA, USA) except for method F. Protein concentra-
tion was estimated using the 2D-Quant kit following the
manufacturer’s instructions (GE Healthcare, Hercules, UK) before
adding the reducing agent and IPG buffer 1% (v/v). IPG buffer (of
the same pH as the strip) was added just before the rehydration
step. 200 mg of sample was loaded onto each 11 cm gel (Method
A–E) and 300 mg was loaded onto the 17 cm gel (Method F). Spot
count was performed for each of the methods using the PDQuest
v7.3.1 (Bio-Rad, CA, USA) spot detection module.
Method A) The sample was mixed with rehydration buffer (RB)
(7 M Urea, 2 M thiourea, 4% CHAPS, 40 mM Tris) and 5 mM
TBP, without a depletion and desalting step, followed by
rehydration on pH 3–10 non-linear (NL) IPG strips (Bio-Rad
Laboratories CA, US).
Method B) Albumin and IgG were depleted from the plasma
using the Aurum serum protein mini kit according to manufac-
turer’s instruction (Bio-Rad Laboratories, CA, US) followed by
blending with RB +5 mM TBP. No desalting was undertaken.
The sample was then rehydrated on a pH 3–10 NL IPG strip.
Method C) Aurum serum depletion was followed by a desalting
process using the Khan et al. protocol [36]. In brief, the Aurum
serum depleted sample was precipitated with ice-cold acetone at
220uC overnight and pelleted at 4000 g for 60 minutes at 10uC.
The pellet was resuspended in RB with 5 mM TBP and 10 mM
acrylamide for 60 minutes. The sample was spun at 21000 g to
remove any insoluble impurities. The sample was then diluted
with 13 ml RB without Tris, and added to 5 kDa 15 ml Amicon
Ultra-15 centrifugal filters (Millipore MA, US). The protein
solution was desalted and concentrated at 20006g until the volume
reached 350 ml. The desalted sample was then rehydrated on the
pH 4–7 IPG strip.
Method D) Aurum serum sample depletion was followed by
sample clean up using the 2D-clean up kit (GE Healthcare,
Hercules, UK) following the manufacturer’s instruction. This kit
removes impurities such as nucleic acids, lipids, and salts. The
clean pellet was resuspended in RB with 65 mM DTT for
reduction for 30 minutes and 130 mM iodoacetoamide for
alkylation for 30 minutes followed by rehydration on pH 4–7
IPG strip.
Method E) Aurum serum depletion was replaced by Multiple
Affinity Removal System (MARS) (Agilent technologies CA, US)
column depletion, undertaken at the Australian Proteome Analysis
Facility (Sydney, Australia). This process removes the top six most
abundant proteins (85%) in plasma, namely albumin, IgG, IgA,
alpha-1 antitrypsin, transferrin, and haptoglobin. The dilute
samples were applied to 5 kDa Amicon Ultra-15 centrifugal filters
(Millipore MA) and spun at 20006g to concentrate the solution to
400 mL. The sample was cleaned using 2D-clean up kit. The
purified protein pellet was suspended in RB followed by a 30
minute reduction step with 65 mM DTT and 30 minute alkylation
with 130 mM acrylamide. The sample was rehydrated on a pH 4–
7 IPG strip.
Method F) The same process was used as in Method E except a
17 cm IPG strip was used instead of an 11 cm strip. The first and
second dimension steps were generally consistent between the
protocols (A–F).
DIGE sample preparation and labelling
The samples, prepared as described in method F were labelled
using fluorescent Cy Dyes as per manufacturer’s Instructions (GE
Healthcare, Hercules, UK). The sample labelling is shown in
Table 1.
2D-Gel electrophoresis
IPG strips (pH 4–7, 11–17 cm, Bio-Rad Laboratories CA,
USA) were rehydrated with the Cy Dye-labelled samples for
18 hours at room temperature. Iso-electric focussing (IEF) was
performed for a total of 95,000 Vh for 17 cm strips and
70,000 Vh for 11 cm strips at 20uC using the IPGphor-II
apparatus (GE Healthcare, Hercules, UK). Strips were equilibrat-
ed prior to SDS-PAGE for 15 minutes in equilibration buffer (6 M
urea, 50 mM Tris pH 8.8, 20% (v/v) glycerol, 2% (w/v) SDS)
with 5 mM TBP and then for 15 minutes in same equilibration
buffer with 2.5% (v/v) acrylamide. The SDS PAGE was run by
laying the strips on 8–18% large size (20 cm620 cm) precast gels
(Jule Inc., CT, US). The strips were overlaid with 1% agarose in
SDS running buffer containing bromophenol blue. Tris-glycine
(24.8 mM Tris, 192 mM glycine, 0.1% (w/v) SDS) running buffer
was used. The 11 cm gels were run on a Criterion gel system (Bio-
Rad laboratories CA, USA) for the 2
nd dimension at 200 V for 40
minutes or until the dye front ran off the bottom of the gel. The
17 cm gels were run at 16 mA/gel for one hour, 20 mA/gel for
the next 3 hours, and 24 mA/gel thereafter until the bromophenol
blue dye front had run off the bottom of the gels. Gels were
scanned immediately. A non-DIGE preparative gel was run with
600 mg protein under the same conditions from a pool of all
samples. This gel was stained with Coomassie blue and was used to
excise spots for protein identification.
Gel imaging
The protocol optimization gels were initially fixed in Fix/Wash
Buffer (10% (v/v) methanol, 7% (v/v) acetic acid) for 1 hour
followed by Sypro Ruby staining overnight. The gels were then
washed with Fix/Wash buffer for 1 hour before scanning with
Typhoon9410 scanner (GE Healthcare, Hercules, UK) following
manufacturer’s instructions. The DIGE images were also scanned
using Typhoon scanner following manufacturer’s protocol for
DIGE images. Image analysis was performed using the DeCyder
software package v5 (GE Healthcare, Hercules, UK), a 2-DE
analysis software specifically designed for DIGE experiments. 2500
spots were identified and quantified using the DeCyder difference
in-gel analysis (DIA) module. Proteins were deemed to be
differentially expressed if they showed greater than 1.5 fold
change in abundance between CR and CNR and p,0.05 using a
1-way ANOVA.
Protein identification
Proteins of interest were excised from the preparative gel for
protein identification. Preparation for protein identification was
undertaken using the protocol described in Gez S. et al. [37]
Peptide mass fingerprints of tryptic peptides were generated by
Table 2. Demographics of patients providing samples for the
targeted approach.
CNR CR
Average age (years) 48611 44613
Gender ratio (F:M) 15:4 13:5
Disease subtype (RRMS:SPMS) 11:8 16:2
Average duration on treatment (years) 4.562.2 3.562.2
doi:10.1371/journal.pone.0010484.t002
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Voyager DE-STR (Applied Biosystems, CA, US). The resulting
data peaks were calibrated with trypsin autolysis peaks (842.51,
1054.56, and 2211.10 Da). The data was visualized using Data
Explorer v4.5 (Applied Biosystems, CA, US) and analysed with
Mascot (Matrix Science, London, UK) for protein identification
comparing it with the MSDB and SWISS-PROT databases.
Protein identifications were assigned to potential matches with an
expectation value less than 0.01 and a score greater than 80. For
higher molecular weight proteins, a more stringent expectation
value (less than 0.001) was used. The spots identified by MALDI-
TOF were confirmed using tandem mass spectrometry on a
QSTAR (Applied Biosystems, CA, US) at the Sydney University
Proteome Research Unit (SUPRU, University of Sydney, Sydney,
Australia).
Power calculations
An ongoing issue with complex proteomic experiments is the
low statistical power of an experiment resulting in an inability to
detect biologically significant changes. In the current study we
used a process of experimental design to estimate the optimal
sample size required to provide adequate statistical power at our
chosen level of significance. Power calculations were conducted
using tools provided by Emphron Informatics (www.emphron.
com) according to the protocol defined by Hunt et al [18]. Breifly,
volumes of 100 spots matched across all the six gels were selected
for the analysis. These spots were randomly selected across the
entire gel to remove any bias towards a particular region of the
gel. The protocol estimates biological and technical variance
between the groups using a mixed effects linear model involving a
fixed term for the difference between groups and random
deviations representing differences between samples and gels.
Due to the use of the 2D-DIGE internal standard and the
associated normalization between gels, the gel-gel difference was
set to null. The software uses the estimated biological (sample)
variation to determine the standard error of differences between
CR and CNR before calculating the number of samples
required to give 80% power (probability of not detecting a
real change in protein expression) when attempting to find
changes in expression of a given size at a given level of statistical
significance (probability of falsely identifying a change in protein
expression).
Cytometric beadarray
Levels of IL-6, IL-8 (CXCL8), IP-10 (CXCL10), MIP-1a
(CCL3), MCP-1 (CCL2), MIG (CXCL9), and Eotaxin (CCL11)
in serum were determined in the chemokine analysis samples by
utilizing a cytometric bead array (CBA) (BD Bioscience, NJ, US)
kit and fluorescence detection by an LSR II flow cytometer (BD
Bioscience, NJ, US). Briefly, 50 ml of beads with different
fluorescence intensities and coated with cytokine or chemokine
specific antibodies were added to 50 ml of diluted patient sera and
incubated for an hour at room temperature in the dark. 50 mlo f
phycoerythrin-conjugated secondary antibody specific to cytokine
or chemokine was added to the mixture and incubated for
2 hours at room temperature away from light. Simultaneously,
standards for each cytokine or chemokine were treated in the
same manner. Beads were washed to remove unbound detection
antibodies and were analysed using a flow cytometer. Cytokine
and chemokine concentrations were estimated using the CBA
software. The statistical significance of the study was calculated
using Wilcoxon’s test with p-values of ,0.05 considered
statistically significant.
Results and Discussion
2D-gel electrophoresis protocol optimization
In optimizing sample preparation protocols for gel electropho-
resis, we seek to resolve the maximum number of spots and to
obtain clear separation between these spots. This improves the
accuracy of subsequent image and mass spectrometric analyses.
In method A (Figure 1A), only the most abundant proteins such
as albumin, haptoglobin, fibrinogen, IgA, and IgG are clearly
visible. To maximize the number of spots seen on the gel we
depleted these highly abundant proteins, as they masked the
presence of less abundant proteins and interfered with their
resolution on the gel. We compared two depletion techniques.
After Aurum serum depletion of albumin and IgG which
constitute 70–80% of the total proteins in plasma (method B–D),
we found the spot resolution was better and display of less
abundant proteins increased as compared to method A. However,
the number of spots remained the same or decreased due to
protein loss (Figure 1A–D). Also, Aurum serum depletion uses
resin blend columns which do not induce absolute removal of the
two proteins; and over 10% of these proteins remain in the sample.
(Figure 1B–D). In Method E and F, the MARS column depletion
showed a further 3–4 fold increase in the number of spots as
compared to Aurum serum depletion (methods B–D, Figure 1E–
F). Depletion with MARS column resulted in removal of
approximately 99% of the top six most abundant proteins which
constitute 85–90% of total proteins in plasma.
In method A and B (Figure 1A and B), horizontal streaking
between the spots is visible, indicating lack of protein separation.
Clear separation between protein spots can be achieved by
removing salts and charged contaminants as these affect iso-
electric focussing. In the current experiment we compared two
different desalting techniques. The first procedure incorporated
desalting via acetone precipitation followed by diafiltration or
buffer exchange [36] (method C). The separation of spots was
better than method A and B but was not uniform across the gel
despite the desalting step. This may be attributed to higher
conductivity and low yield of protein prevented further rounds of
buffer exchange as it would decrease the conductivity at the cost of
higher protein loss. The second desalting procedure uses a 2D-
clean up kit (Figure 1D–F). Despite using similar concentration to
begin with, the protein concentration after 2D-clean up (1.2 mg/
ml) was high compared to the buffer exchange method (0.73 mg/
ml) indicating the former results in lesser protein loss. The protein
separation was enhanced, protein loss was minimized, and
desalting efficiency was improved with the 2D-clean up kit as
compared to the single buffer exchange method.
In Method D (Figure 1D), horizontal streaking was completely
removed, except in some parts of the gel at the acidic end which
showed aggregate formation during the iso-electric focussing step.
This issue was eliminated by the use of acrylamide as an alkylating
agent instead of iodoacetamide before iso-electric focussing as
shown in (Figure 1E). Iodoacetamide may induce cross reactivity
with thiourea which could have caused improper alkylation,
leading to reformation of disulfide bridges and hence the streaking
at positive end [38]. Thus, we found acrylamide to be a better
alkylating agent than iodoacetamide.
Finally, in method F, the 17 cm gel showed a better separation
of protein spots due to larger gel size (Figure 1F). Thus, it was
determined to be the most appropriate technique for of depleting
abundant proteins, desalting, and alkylation of the sample before
isoelectric focussing ensured a lower protein loss resulting in a
greatly increased number of spots displayed on a 2D-gel image
with proper separation to help with further analysis and spot
Proteomics and IFNb Treatment
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and running of the DIGE gels.
Power analysis
The primary aim of the discovery driven approach was to
produce sufficient 2D-DIGE data to enable statistical power
calculations to determine optimal sample size. DIGE studies use
an internal standard to help eliminate gel-to-gel variation [39].
However, normal biological variation between the samples
remains and this can lead to false conclusions as this variation
interferes with the ability to detect variation between the groups of
interest. Proteomic studies require sufficient statistical power to
overcome these sources of variation. To address this issue, we
conducted power calculations based on the modified protocol of
Hunt et al [18]. To our knowledge this is first DIGE study which
incorporates power calculations to determine optimal sample size.
The power analysis tool was used to calculate the minimal
detectable difference defined as the size of effect required to give a
chosen statistical power at a specific significance level. The results
are shown in Figure 2. The power calculation showed that a
minimum of 10 biological variants from each group are required
to be confident of a 1.5-fold (50% effect size) and 2 fold (100%
effect size) change in abundance between CR and CNR at the
p,0.05 and p,0.005 level of statistical significance respectively.
Identification of differentially abundant proteins
The secondary aim of the discovery driven approach was to
identify differentially abundant proteins detectable with the
existing sample size. The power analysis indicated an optimal
sample size of 10. This means ten samples per groups are required
in order to be reasonably certain of detecting statistically
significant (p,0.05) changes in protein expression at least 1.5 fold
in size. However, it still remains possible, albeit less likely, to find
statistically significant changes using smaller sample sizes,
particularly if the fold-change is greater than 1.5. In statistical
terms, the use of a smaller sample size does not affect Type I error
(falsely deciding a protein is differentially expressed) but will
increase Type II error (not detecting proteins that are actually
differentially expressed). As the three-sample-per-group analysis
was required in order to conduct the power calculations, we chose
Figure 1. 2DE gel images of human plasma samples generated with the different sample preparation methods used during
optimization. Method A) Crude plasma - 224 spots, Method B) Aurum serum depleted plasma without desalting– 86 spots, Method C) Aurum
serum depleted plasma desalted according to Khan et al. protocol– 78 spots, Method D) Aurum serum depleted plasma cleaned up using 2D-clean
up kit and alkylated using iodoacetamide - 212 spots Method E) MARS depleted plasma followed by 2D-clean up and alkylated using acrylamide– 774
spots, Method F) 17 cm gel with same protocol as E– 1041 spots. Each ladder had molecular weight ranging from 10 to 220 KDa.
doi:10.1371/journal.pone.0010484.g001
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biomarkers.
The DeCyder biological variation analysis (BVA) module was used
to match spot maps and conduct statistical analysis to identify
differentially expressed spots based on the standard abundance value
for each spot. Three spots were found to be more abundant in clinical
responders to IFNb as compared to non-responders with a fold
difference of at least 1.5 at the p,0.05 level of significance (Figure 3)
(Table 3). These spots were identified as Alpha 2 macroglobulin
(A2M), Apolipoprotein A1 (APOA1), and Fibrinogen B (FIBB) using
MALDI-TOF mass spectrometry (Figure 3) (Table 3). The protein
identification was further confirmed using tandem mass spectrometry
where three peptides were matched for each protein.
A2M is a known inhibitor of matrix metalloproteinase activity
(MMP2 and MMP9) along with their other tissue inhibitors
(TIMP1 and TIMP2) [40]. Previous studies have shown no
difference in the plasma level of total A2M between MS and HC
[41,42] however both MMP9 and the MMP9:TIMP1 ratio in the
serum of MS patients are high compared to HC [43] while these
levels are reduced in patients treated with IFNb [44]. A recent
study showed that TIMP-1 levels increased longitudinally in
clinical responders to IFNb treatment as compared to clinical non-
responders [45]. Together with our finding that MMP inhibitor
A2M levels are increased in the plasma of CRs compared to
CNRs, the data suggest that matrix metalloproteinase inhibitors
may prove useful as clinical response markers to IFNb treatment
in MS. A2M has previously been found to be downregulated in
CSF in a study comparing RRMS with other neurological diseases
and a separate study comparing HIV-1 with and without dementia
[46]. This suggests any pathogenic link with MS may not be
specific. Functional studies, such as phenotype characterisation
studies, would help address this question.
APOA1 levels were significantly lower in plasma at the end of
the first year of treatment in patients treated with IFNb, who
suffered relapses after therapy or progressed in their EDSS score,
as compared to their basal values [47]. While there was no
significant difference between the CRs and CNRs, there was a
trend towards down regulation in non-responders, which concurs
with our analysis. APOA1 acts as an inhibitory factor for
proinflammatory cytokines IL-1b and TNFa that have been
suggested to have a role in MS pathogenesis [48]. The same
research group also showed IFNb inhibits the ability of T-cells to
induce IL-1b and TNFa [49]. Thus IFNb may induce APOA1
which inhibits the activity of proinflammatory cytokines in CRs.
APOA1 is also responsible for the inhibition of adhesion molecules
ICAM-1 and VCAM-1 [50], that assist in auto-reactive T-cell
extravasation through the blood brain barrier (BBB) in MS
pathogenesis [51]. Thus, APOA1 is a putative clinical response
marker to IFNb treatment that should be further validated.
To our knowledge, there is no known association between FIBB
and IFNb treatment or FIBB and MS.
Timms and Cramer recently reviewed the utility of DIGE as a
quantitative technique [52]. They found DIGE has a number of
strengths as a quantitative technique but also certain limitations.
Figure 2. Power curve showing the minimum % effect size (fold change) detectable as a function of sample size with 80% power at
two different significance levels.
doi:10.1371/journal.pone.0010484.g002
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common with other quantitative approaches, suggesting the
various techniques are complementary. Thus, a follow-on study,
using the optimal sample size determined in this study, and
incorporating validation with a second quantitative method, is
desirable to confirm the status of the differentially expressed
proteins identified in this study as putative clinical response
markers.
Figure 3. A 2D-DIGE image comparing the plasma proteome of CR to IFNb treatment with CNR to IFNb treatment with Cy3 and Cy5
channel overlap. Samples were run on 17 cm gels after clean up and depletion. Spots Sp1, Sp2, and Sp3 were found to be increased in CR as
compared to CNR based on a 1-way ANOVA with a p-value of less than 0.05 and fold change greater than 1.5.
doi:10.1371/journal.pone.0010484.g003
Table 3. Differentially expressed spots between CR and CNR with p-value ,0.05 and fold change .1.5.
No Fold Protein p Score E-value Match mW/pI
sp1 2.12 Alpha-2 macroglobulin 0.034 88 3.1610
25 12 164951/6.00
sp2 2.1 Fibrinogen beta chain 0.025 86 4.1610
25 12 56745/8.54
sp3 1.72 Apolipoprotein A1 0.049 124 7.2610
29 11 30759/5.56
No is the spot number; Fold is the fold change in expression; p is the p-value associated with the fold change in expression; Score and expectation value (E-value)
indicate the confidence of protein identification; Match is the number of matching peptides; mW/pI is the theoretical molecular weight and isoelectric point as
calculated from Mascot database; all spots were confirmed with tandem mass spectrometry.
doi:10.1371/journal.pone.0010484.t003
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IL-6 (p=0.2), IL-8 (p=0.53), MIG (p=0.3), MCP-1 (p=0.61),
eotaxin (p=0.11), IP-10 (p=0.81), and MIP-1a (p=0.61) serum
concentrations were not significantly different between CR and
CNR to IFNb. However, both eotaxin and IL-6 levels were high in
CR as compared to CNR, but not significantly different, partly
because some of the samples were below the level of detection
(Figure 4). Eotaxin is produced by Th2 cells [53] and has
previously been found to be reduced in serum of MS patients as
compared to HC [32]. Hence a trend towards elevation of serum
eotaxin in CRs could be an effect of Th2 bias generated by IFNb
treatment. CR also showed a trend towards a higher percentage of
samples with detectable serum IL-6, another Th2 cytokine.
Interestingly, increased IL-6 in IFNb treated patients has been
found to be associated with lower relapse rates and disability [54].
There was also no significant difference in the serum
concentrations between NAB+ve and NAB-ve patients of any of
the analytes: IL-6 (p=0.99), IL-8 (p=0.43), MIG (p=0.92),
MCP-1 (p=0.77), Eotaxin (p=0.33), IP-10 (p=0.23), and MIP-
1a (p=0.21).
Concluding remarks
In summary, we identified an optimal depletion and desalting
technique for gel-based plasma proteomics in clinical samples from
MS patients. The pilot DIGE experiment identified A2M,
APOA1, and FIBB as putative clinical response markers for IFNb
treatment. This study for the first time incorporates power
calculations in a 2D-gel approach to determine the optimal
sample size required to be confident to characterize clinical
response markers. The targeted approach suggests that eotaxin
and IL-6 require further investigation as possible IFNb clinical
response markers.
Both discovery-driven and targeted approaches demonstrated a
requirement for a larger sample size to fully characterize clinical
response markers using a proteomic approach. Furthermore,
heterogeneity in multiple sclerosis itself, as well as the approaches
to treatment with IFNb, also suggests the need for larger sample
sizes to help eliminate others sources of biological variability not
directly related to the effect of IFNb treatment. Thus, while we
have identified an initial set of putative biomarkers, there are
almost certainly more to discover through future studies involving
larger sample sizes. This may increase the detectable differences in
the protein profile between CR and CNRs, which may help
identify more putative biomarkers, and improve our understand-
ing of the mechanism of action of IFNb in the treatment of
multiple sclerosis.
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